{"meta":{"totalResults":1,"from":0},"results":[{"aliases":[{"type":"USBrandName","name":"Faslodex"},{"type":"LexicalVariant","name":"ICI 182780"},{"type":"LexicalVariant","name":"ICI182780"},{"type":"ChemicalStructureName","name":"7a-[9-[(4,4,5,5,5,-Pentafluoropentyl)sulphinyl]nonyl]-estra-1,3,5(10)-triene-3,17b-diol"},{"type":"CodeName","name":"ICI 182,780"},{"type":"CodeName","name":"ZD9238"},{"type":"NSCNumber","name":"719276"},{"type":"CASRegistryName","name":"129453-61-8"}],"definition":{"html":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines.","text":"A synthetic estrogen receptor antagonist.  Unlike tamoxifen (which has partial agonist effects) and the aromatase inhibitors (which reduce the estrogen available to tumor cells), fulvestrant binds competitively to estrogen receptors in breast cancer cells, resulting in estrogen receptor deformation and decreased estrogen binding. In vitro studies indicate that fulvestrant reversibly inhibits the growth of tamoxifen-resistant, estrogen-sensitive, human breast cancer cell lines."},"drugInfoSummaryLink":{"uri":"https://www.cancer.gov/about-cancer/treatment/drugs/fulvestrant","text":"Fulvestrant"},"nciConceptId":"C1379","nciConceptName":"Fulvestrant","termId":43053,"name":"fulvestrant","firstLetter":"f","type":"DrugTerm","termNameType":"PreferredName","prettyUrlName":"fulvestrant"}],"links":null}